Company Response
Bristol-Myers Squibb has not responded to
Oxfam report says top drug companies focusing on patents, not the poor
Timeline
-
Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"
-
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
Oxfam report "Investing for Life": Company responses
-
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos
Available languages: español -
Oxfam says top drug companies focusing on patents, not poor
-
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments
Available languages: français -
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
-
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices
View full story